171 related articles for article (PubMed ID: 27742656)
1. Pembrolizumab induced severe sclerodermoid reaction.
Shenoy N; Esplin B; Barbosa N; Wieland C; Thanarajasingam U; Markovic S
Ann Oncol; 2017 Feb; 28(2):432-433. PubMed ID: 27742656
[No Abstract] [Full Text] [Related]
2. Generalized morphea in the setting of pembrolizumab.
Cheng MW; Hisaw LD; Bernet L
Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
[No Abstract] [Full Text] [Related]
3. Generalised morphea induced by pembrolizumab.
Herrscher H; Tomasic G; Castro Gordon A
Eur J Cancer; 2019 Jul; 116():178-181. PubMed ID: 31202088
[No Abstract] [Full Text] [Related]
4. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
[No Abstract] [Full Text] [Related]
5. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
Haddox CL; Shenoy N; Shah KK; Kao JC; Jain S; Halfdanarson TR; Wijdicks EF; Goetz MP
Ann Oncol; 2017 Mar; 28(3):673-675. PubMed ID: 27993808
[No Abstract] [Full Text] [Related]
6. Pembrolizumab-Induced Alopecia Areata.
Elshimy N; Blakeway E; Mitra A
Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
[No Abstract] [Full Text] [Related]
7. Pembrolizumab-Related Sarcoid-Like Reaction Presenting as Reactivation of Quiescent Scars.
McKenna MC; Molloy K; Crowther S; Feeney J; Gillis A; Connolly M; Kelleher F
J Oncol Pract; 2018 Mar; 14(3):200-201. PubMed ID: 29300520
[No Abstract] [Full Text] [Related]
8. Vasculitic neuropathy induced by pembrolizumab.
Aya F; Ruiz-Esquide V; Viladot M; Font C; Prieto-González S; Prat A; Arance A
Ann Oncol; 2017 Feb; 28(2):433-434. PubMed ID: 27864214
[No Abstract] [Full Text] [Related]
9. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
Amini-Adle M; Balme B; Dalle S
Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
[No Abstract] [Full Text] [Related]
10. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
[No Abstract] [Full Text] [Related]
11. Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
Algaeed M; Mukharesh L; Heinzelmann M; Kaminski HJ
Neurology; 2018 Oct; 91(14):e1365-e1367. PubMed ID: 30275130
[No Abstract] [Full Text] [Related]
12. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma.
Vallet H; Gaillet A; Weiss N; Vanhaecke C; Saheb S; Touitou V; Franck N; Kramkimel N; Borden A; Touat M; Ricard D; Verny M; Maisonobe T; Psimaras D
Ann Oncol; 2016 Jul; 27(7):1352-3. PubMed ID: 26940685
[No Abstract] [Full Text] [Related]
13. Drug-associated vasculitis occurring after treatment with pembrolizumab.
Tolaymat OA; Pinkston O; Wang B; Schenk WB; Joseph RW; Mergo PJ; Berianu F
Rheumatology (Oxford); 2019 Aug; 58(8):1501-1503. PubMed ID: 30892627
[No Abstract] [Full Text] [Related]
14. Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma.
Denny J; Chong H; Akhras V
Clin Exp Dermatol; 2018 Apr; 43(3):354-356. PubMed ID: 29222829
[No Abstract] [Full Text] [Related]
15. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
16. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
17. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
Nardin C; Pelletier F; Puzenat E; Aubin F
Acta Derm Venereol; 2019 Sep; 99(10):913-914. PubMed ID: 31017249
[No Abstract] [Full Text] [Related]
18. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
19. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
20. An Unusual Case of Synchronous Metastatic Melanomas With Differing Response to Pembrolizumab.
Doolan BJ; McLean C; Mar V; Moore M
J Oncol Pract; 2019 Mar; 15(3):159-160. PubMed ID: 30861362
[No Abstract] [Full Text] [Related]
[Next] [New Search]